Agentic Revenue Integrity Needs a Control Plane
Editorial revision: . Original publication and source dates are retained.
How agentic revenue integrity connects prior authorization, claims, denials, payment integrity, evidence, human review, and financial proof without turning consequential healthcare decisions into black-box automation.
Return to insightsHealthcare CFOs, RCM leaders, payer and provider operators, healthtech founders, and product teams designing agentic revenue workflows. / 2026-07-16
The strategic question
How should agents operate across revenue integrity without creating a faster, less explainable version of the same fragmented workflow?
Frames agentic revenue integrity as a governed operating architecture. It does not endorse autonomous denial or patient-impact actions and does not claim unverified savings.
Executive thesis
Control the transaction across its handoffs.
My thesis is that a revenue-integrity control layer earns its cost by preserving one explainable transaction across organizational handoffs. Eligibility, authorization, coding, claims, denials and appeals may each improve locally while the complete transaction remains unresolved. An agent that accelerates one queue can worsen another if it acts on an outdated coverage record or a policy version the receiving team does not recognize.
The architecture must therefore control state as well as access. Before an action proceeds, the organization should know which record is current, which evidence supports the action, whether another actor is already working the case and what event closes it. These are proposed operating requirements. They do not imply that a shared platform acquires clinical or coverage authority merely because it can see several systems.
Public facts
CMS requires impacted payers to report prior-authorization metrics and states that some authorization decisions will continue to require clinical review even as API automation expands.
CMS's Medicaid Integrity Program combines oversight, education, technical assistance, program reviews, and best practices rather than treating integrity as a single detection tool.
NIST's AI RMF Core calls for lifecycle governance, documented roles, human-AI responsibilities, measurement, monitoring, and accountable executive ownership.
HHS positions AI implementation and governance together, linking operational use with public trust rather than treating governance as a separate afterthought.
Operator read
Revenue operations fail at handoffs: documentation to authorization, authorization to scheduling, coding to claim, denial to appeal, finding to provider communication, and identified opportunity to validated value.
Agents are most useful when they can read the shared operating context and move bounded work across those handoffs. They are least trustworthy when each agent carries its own private logic, memory, permissions, and success metric.
A control plane makes the shared objects, policies, permissions, queues, evidence, owners, and outcomes visible. That is what allows automation to scale without losing accountability.
Payer and provider value must be evaluated together. Faster edits or denials can look efficient while increasing access friction, appeals, provider abrasion, and downstream rework.
Operating model
Reconcile the complete revenue obligation.
I would define the transaction at a level that survives the handoff: patient and encounter identity, service, coverage period, authorization reference, claim version, adjustment history and outstanding obligation. Record the responsible party at each state and preserve the link to supporting evidence. A contested action should reopen the appropriate obligation without erasing the prior decision or duplicating the financial result.
The CFO’s review should reconcile the full cohort from service to settlement. Report preventable denials, corrected errors, valid recoveries, time to cash and the cost of disputes separately. Earlier collection is a working-capital benefit; an increase in collectible revenue is a different source of value. Vendor pricing and internal attribution should prevent two teams from claiming the same recovered dollar.
The decision to add an orchestration layer is comparative. Compare its total cost with a narrower repair to the existing process. If the dominant failure is one missing field or one under-resourced team, a system-wide platform may be excessive. If recurring failures cross boundaries and cannot be resolved within a single owner’s authority, the shared layer has a stronger case. I would expand only after it reduces unresolved obligations across the full pathway without creating a larger review burden.
Operating framework
- 01
Create a shared object model for member, patient, provider, authorization, claim, denial, policy, contract, evidence, appeal, payment, and outcome.
- 02
Separate agent permissions for finding, assembling, recommending, routing, communicating, and executing work.
- 03
Use risk tiers to determine where deterministic controls, human review, clinical judgment, or dual approval are required.
- 04
Instrument evidence lineage, ownership, exception queues, model or rule version, action history, and financial outcome.
- 05
Measure the whole workflow across access, revenue, quality, provider impact, operating cost, and validated value.
Metrics that matter
- 01
Time from service to final settlement by cohort
- 02
Preventable denial rate and cost of correcting each episode
- 03
Aged exceptions relative to funded review capacity
- 04
Contested actions reproducible from source and approval history
- 05
Retained incremental value after fees, appeals and operating cost
- 06
Access delays and unresolved obligations transferred to other teams
Buyer implications
The platform decision is an operating-architecture decision, not only an AI feature comparison.
Finance, revenue cycle, utilization, clinical, network, security, legal, product, and operations teams need one action and evidence model.
Agent permissions should be role-based and risk-tiered, with clear boundaries between recommendation, communication, and execution.
The pilot should prove end-to-end workflow value and auditability, not the productivity of a single task agent.
Founder actions
Map the shared revenue-integrity objects and handoffs before designing agents.
Define permission tiers and human-review rules for every action type.
Instrument exceptions, evidence lineage, versioning, action history, and final financial outcome.
Build one bounded cross-workflow path before launching an agent catalog.
Report value net of implementation, human review, appeals, rework, and provider impact.
Red flags
Agents can take consequential actions without explicit permission boundaries or named human owners.
The architecture automates portals and tasks but preserves fragmented data, queues, and accountability.
The value case ignores exception handling, adoption, appeals, monitoring, and integration cost.
The product cannot reconstruct which evidence, policy, rule, model, and reviewer produced an action.
CEO and CFO questions
Which cross-organizational failure justifies a shared control layer rather than a narrower process repair?
Which permissions remove a material constraint, and what new exposure accompanies each permission?
Who can accept the clinical or financial consequence, and is that decision capacity funded?
What exception age, error concentration or review burden will trigger a restriction of scope?
What retained cash remains after implementation, review, disputes and correction, without double-counting recoveries?
Before expanding agent permissions, confirm that leadership can reconstruct the evidence, authority, human review, and financial outcome of each consequential action.
Design the revenue integrity control planeDiscuss the strategic decision